Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis

Adv Exp Med Biol. 2003:528:521-3. doi: 10.1007/0-306-48382-3_104.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Behcet Syndrome / drug therapy*
  • Follow-Up Studies
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Recombinant Proteins
  • Retinal Vasculitis / drug therapy*
  • Retinal Vasculitis / etiology
  • Time Factors
  • Treatment Outcome
  • Uveitis, Anterior / drug therapy*
  • Uveitis, Anterior / etiology
  • Uveitis, Posterior / drug therapy*
  • Uveitis, Posterior / etiology
  • Visual Acuity*

Substances

  • Angiogenesis Inhibitors
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins